Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 115 full-time employees. The company went IPO on 2018-10-04. The firm has developed a technology platform for retinal medicines. The firm is engaged in preventing and treating the major causes of blindness by developing and commercializing next-generation therapeutics for chronic, high-prevalence retinal diseases. The Company’s ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s product candidate, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its KSI-501 is a dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases.